Literature DB >> 20552592

The causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry).

Cheng-I Cheng1, Ching-Pei Chen, Pei-Liang Kuan, Meng-Huan Lei, Chiau-Suong Liau, Kwo-Chang Ueng, Chiung-Jen Wu, Wen-Ter Lai.   

Abstract

BACKGROUND: Benefits of antiplatelet agents in preventing future cardiovascular events have been well established. However, the prescription pattern of antiplatelet usage in patients with acute coronary syndrome (ACS) is rarely investigated. Hence, Taiwan ACute CORonary Syndrome Descriptive Registry (T-ACCORD Registry) aimed to evaluate medical practices in Taiwan in managing ACS patients. HYPOTHESIS: The guidelines of antiplatelet treatment is not properly implanted in the management of ACS patients.
METHODS: This prospective observational study was performed between April 2004 and December 2006 in 27 hospitals in Taiwan. A total of 1331 patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) discharged from hospitals was analyzed.
RESULTS: The patients with older age, lower hemoglobin levels, or previous cardiovascular ischemic diseases were less likely to receive aspirin at discharge, whereas patients with NSTEMI were less likely to receive clopidogrel at discharge. The prescription of dual antiplatelet agents declined rapidly from 61.8% at discharge to 12.6% at 12 months. The most common reason for clopidogrel discontinuation was recorded as physician's judgment. Dual antiplatelet treatment for 9 months or longer was associated with lower 1-year mortality. Percutaneous coronary intervention (PCI) was the only factor leading to dual antiplatelet therapy for at least 9 months.
CONCLUSIONS: Our registry showed that underlying medical conditions may affect antiplatelet prescriptions at discharge. During the first year following an ACS episode, the prescription rate of dual antiplatelet therapy declined over time, mainly due to physician's judgment leading to the discontinuation of clopidogrel. Adherence to dual antiplatelet treatment was associated with lower total mortality at 1 year.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20552592      PMCID: PMC6653408          DOI: 10.1002/clc.20730

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  11 in total

Review 1.  The Management and Prognostic Factors of Acute Coronary Syndrome: Evidence from the Taiwan Acute Coronary Syndrome Full Spectrum Registry.

Authors:  Chun-Yuan Chu; Tsung-Hsien Lin; Wen-Ter Lai
Journal:  Acta Cardiol Sin       Date:  2017-07       Impact factor: 2.672

2.  One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry.

Authors:  Juan Miguel Ruiz-Nodar; María Asunción Esteve-Pastor; Jose Miguel Rivera-Caravaca; Miriam Sandín; Teresa Lozano; Nuria Vicente-Ibarra; Esteban Orenes-Piñero; Manuel Jesús Macías; Vicente Pernías; Luna Carrillo; Elena Candela; Andrea Veliz; Antonio Tello-Montoliu; Juan Gabriel Martínez Martínez; Francisco Marín
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

3.  Safety and Cumulative Incidence of Major Cardiovascular Events with Ticagrelor in Taiwanese Patients with Non-ST-Segment Elevation Myocardial Infarction: A 12-Month, Prospective, Phase IV, Multicenter, Single-Arm Study.

Authors:  Guang-Yuan Mar; Wilhelm Ridderstråle; Jianxin Wei; Chun-Peng Liu
Journal:  Acta Cardiol Sin       Date:  2020-05       Impact factor: 2.672

4.  Current discharge management of acute coronary syndromes: data from the Rijnmond Collective Cardiology Research (CCR) study.

Authors:  T Yetgin; M M J M van der Linden; A G de Vries; P C Smits; R van Mechelen; S C Yap; E Boersma; F Zijlstra; R-J M van Geuns
Journal:  Neth Heart J       Date:  2014-01       Impact factor: 2.380

5.  Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea.

Authors:  Hee Ja Byeon; Young-Mo Yang; Eun Joo Choi
Journal:  Ther Clin Risk Manag       Date:  2016-02-12       Impact factor: 2.423

6.  Use of medicines recommended for secondary prevention of acute coronary syndrome.

Authors:  Mari Ângela Gaedke; Juvenal Soares Dias da Costa; Euler Roberto Fernandes Manenti; Ruth Liane Henn; Vera Maria Vieira Paniz; Marcelo Felipe Nunes; Monique Adriane da Motta; Maria Teresa Anselmo Olinto
Journal:  Rev Saude Publica       Date:  2016-01-15       Impact factor: 2.106

Review 7.  Adherence to Cardiac Practice Guidelines in the Management of Non-ST-Elevation Acute Coronary Syndromes: A Systematic Literature Review.

Authors:  Josien Engel; Nikki L Damen; Ineke van der Wulp; Martine C de Bruijne; Cordula Wagner
Journal:  Curr Cardiol Rev       Date:  2017

8.  Current practice of percutaneous coronary intervention on patients with acute coronary syndrome in Iran: A prospective observational study.

Authors:  Seyed Hashem Sezavar; Morteza Hassanzadeh; Davood Akhlagh Moayed; Mahmood Tabandeh; Massoud Ghasemi; Seifollah Abdi; Iraj Firoozi; Pejman Golbidi; Marzieh Pourjafari; Negin Taslimi; Ali Asghar Akhlaghi; Mahmoud Hashemian
Journal:  Med J Islam Repub Iran       Date:  2020-02-27

9.  Profiles of Hospitalized Patients with Angiographic Coronary Heart Disease in Taiwan during 2014-2016: Report of a Tertiary Hospital.

Authors:  Wen-Yu Lin; Yuan Hung; Gen-Min Lin; Chin-Sheng Lin; Jun-Ting Liou; Cheng-Chung Cheng; Tsung-Neng Tsai; Wei-Che Tsai; Tzu-Chiao Lin; Wen-Cheng Liu; Pang-Yen Liu; Keng-Yi Wu; Chih-Hsueng Hsu; Fang-Han Yu; Shu-Meng Cheng; Shih-Ping Yang; Wei-Shiang Lin; Chun-Hsien Wu
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

10.  Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2).

Authors:  Seyed Ebrahim Kassaian; Farzad Masoudkabir; Hashem Sezavar; Mohammad Mohammadi; Ali Pourmoghaddas; Javad Kojuri; Samad Ghaffari; Hamidreza Sanaati; Farshid Alaeddini; Bahin Pourmirza; Elham Mir
Journal:  BMJ Open       Date:  2015-12-15       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.